Shen Kuang-Hsuan, Wang Yu-Hsuan, Hsu Ting-Wei, Hsieh Li-Chun, Sun Fang-Ju, Wang Ying-Piao
Department of Otolaryngology Head and Neck Surgery, Mackay Memorial Hospital, Taipei, Taiwan.
School of Medicine, Mackay Medical College, New Taipei City, Taiwan.
Am J Otolaryngol. 2019 Jan-Feb;40(1):22-29. doi: 10.1016/j.amjoto.2018.09.005. Epub 2018 Sep 13.
The efficacy of postoperative oral corticosteroids on surgical outcomes in chronic rhinosinusitis with nasal polyps (CRSwNP) patients following endoscopic sinus surgery (ESS) remains controversial. This study evaluated the potential benefits of postoperative oral corticosteroids on surgical outcomes in CRSwNP patients and investigated the differential effects on eosinophilic CRSwNP (ECRSwNP) and noneosinophilic CRSwNP (NECRSwNP).
Patients with bilateral CRSwNP who underwent ESS were enrolled and randomized to receive either oral prednisolone (30 mg/day) or placebo for 2 weeks after surgery. Visual analog scale (VAS) and Sino-Nasal Outcome Test 22 (SNOT-22) scores were chosen as the subjective outcomes, evaluated at preoperative baseline and 1, 3, and 6 months postoperatively. Lund-Kennedy Endoscopic Scores (LKESs) were used as the objective outcome, evaluated at preoperative baseline and at 2 weeks and 2, 3, and 6 months postoperatively.
In total, 100 patients with bilateral CRSwNP were enrolled, of whom only 82 completed the 6-month follow-up. The subjective outcomes showed no significant difference at each follow-up points. Of the objective outcomes, the corticosteroid group reporting a trend of improvement in LKESs at 6 months postoperatively (p = 0.05). After stratification by tissue eosinophils, only patients with NECRSwNP (<10 eosinophils/HPF) demonstrated a significant improvement in LKESs at 3 months postoperatively (p = 0.03).
Postoperative oral corticosteroids did not provide additional improvements in VAS and SNOT-22 scores; nevertheless, a trend of LKES improvement was noted at 6 months postoperatively. After stratification by tissue eosinophils, this effect was significant only among NECRSwNP patients at 3 months follow-up.
鼻息肉型慢性鼻-鼻窦炎(CRSwNP)患者行鼻内镜鼻窦手术(ESS)后口服糖皮质激素对手术效果的影响仍存在争议。本研究评估了CRSwNP患者术后口服糖皮质激素对手术效果的潜在益处,并研究了其对嗜酸性粒细胞性CRSwNP(ECRSwNP)和非嗜酸性粒细胞性CRSwNP(NECRSwNP)的不同影响。
纳入行ESS的双侧CRSwNP患者,随机分为术后接受口服泼尼松龙(30mg/天)或安慰剂治疗2周。选择视觉模拟量表(VAS)和鼻窦结局测试22(SNOT-22)评分作为主观指标,在术前基线以及术后1、3和6个月进行评估。采用Lund-Kennedy内镜评分(LKES)作为客观指标,在术前基线以及术后2周、2、3和6个月进行评估。
共纳入100例双侧CRSwNP患者,其中仅82例完成了6个月的随访。主观指标在各随访时间点均无显著差异。客观指标方面,糖皮质激素组术后6个月LKES有改善趋势(p = 0.05)。按组织嗜酸性粒细胞分层后,仅NECRSwNP(嗜酸性粒细胞<10/HPF)患者术后3个月LKES有显著改善(p = 0.03)。
术后口服糖皮质激素未使VAS和SNOT-22评分有额外改善;然而,术后6个月LKES有改善趋势。按组织嗜酸性粒细胞分层后,该效应仅在随访3个月的NECRSwNP患者中显著。